Key result
Alemtuzumab induction before cardiac transplantation yielded similar 12-month survival but higher freedom from rejection vs no induction.
Why the study?
Does alemtuzumab induction improve survival and freedom from rejection in patients undergoing cardiac transplantation?
Cohort (n=220)
No
Does alemtuzumab induction improve survival and freedom from rejection in patients undergoing cardiac transplantation?
Alemtuzumab induction prior to cardiac transplantation allows for steroid-free, lower-intensity calcineurin inhibitor maintenance while significantly reducing rejection rates at 1 year.
Answers are grounded in this paper and cite their sources.
May support alemtuzumab induction to improve rejection-free survival after cardiac transplant; hypothesis-generating and requires randomized confirmation.
Induction therapy with alemtuzumab (C-1H) prior to cardiac transplantation (CTX) may allow for lower intensity maintenance immunosuppression. This is a retrospective study of patients who underwent CTX at a single institution from January 2001 until April 2009 and received no induction versus induction with C-1H on a background of tacrolimus and mycophenolate. Those with C-1H received dose-reduced calcineurin inhibitor and no steroids. A total of 220 patients were included, 110 received C-1H and 110 received no induction. Recipient baseline characteristics, donor age and gender were not different between the two groups. Mean tacrolimus levels (ng/mL) for C-1H versus no induction: months 1-3 (8.5 vs. 12.9), month 4-6 (10.2 vs. 13.0), month 7-9 (10.2 vs. 11.9) and month 10-12 (9.9 vs. 11.3) were all significantly lower for the C-1H group, p < 0.001. There were no differences between the C-1H and no induction groups at 12 months for overall survival 85.1% versus 93.6% p = 0.09, but freedom from significant rejection was significantly higher for the C-1H group, 84.5% versus 51.6%, p < 0.0001. In conclusion, induction therapy after CTX with C-1H results in a similar 12 month survival, but a greater freedom from rejection despite lower calcineurin levels and without the use of steroids.
No takes yet. Share an insight, caveat, or question.
Teuteberg et al. (2009) conducted a cohort in Cardiac transplantation (n=220). Alemtuzumab (C-1H) induction vs. No induction was evaluated on Overall survival at 12 months (p=0.09). Alemtuzumab induction before cardiac transplantation yielded similar 12-month survival but higher freedom from rejection vs no induction.
Synapse has enriched 10 related papers. Consider them for comparative context: